School of Pharmacy, Wingate University, Wingate, NC, USA.
Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
Int J Chron Obstruct Pulmon Dis. 2014 May 3;9:421-30. doi: 10.2147/COPD.S51012. eCollection 2014.
Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that affects an estimated 10% of the world's population over the age of 40 years. Worldwide, COPD ranks in the top ten for causes of disability and death. Given the significant impact of this disease, it is important to note that acute exacerbations of COPD (AECOPD) are by far the most costly and devastating aspect of disease management. Systemic steroids have long been a standard for the treatment of AECOPD; however, the optimal strategy for dosing and administration of these medications continues to be debated.
To review the use of corticosteroids in the treatment of acute exacerbations of COPD.
Literature was identified through PubMed Medline (1950-February 2014) and Embase (1950-February 2014) utilizing the search terms corticosteroids, COPD, chronic bronchitis, emphysema, and exacerbation. All reference citations from identified publications were reviewed for possible inclusion. All identified randomized, placebo-controlled trials, meta-analyses, and systematic reviews evaluating the efficacy of systemic corticosteroids in the treatment of AECOPD were reviewed and summarized.
The administration of corticosteroids in the treatment of AECOPD was assessed. In comparison to placebo, systemic corticosteroids improve airflow, decrease the rate of treatment failure and risk of relapse, and may improve symptoms and decrease the length of hospital stay. Therefore, corticosteroids are recommended by all major guidelines in the treatment of AECOPD. Existing literature suggests that low-dose oral corticosteroids are as efficacious as high-dose, intravenous corticosteroid regimens, while minimizing adverse effects. Recent data suggest that shorter durations of corticosteroid therapy are as efficacious as the traditional treatment durations currently recommended by guidelines.
Systemic corticosteroids are efficacious in the treatment of AECOPD and considered a standard of care for patients experiencing an AECOPD. Therefore, systemic corticosteroids should be administered to all patients experiencing AECOPD severe enough to seek emergent medical care. The lowest effective dose and shortest duration of therapy should be considered.
慢性阻塞性肺疾病(COPD)是一种慢性进行性疾病,估计影响了全球 40 岁以上人群的 10%。在全球范围内,COPD 在导致残疾和死亡的疾病中排名前十。鉴于这种疾病的重大影响,需要注意的是,COPD 的急性加重(AECOPD)是迄今为止疾病管理中最昂贵和最具破坏性的方面。全身皮质类固醇长期以来一直是治疗 AECOPD 的标准;然而,这些药物的剂量和给药的最佳策略仍在争论中。
回顾皮质类固醇在治疗 COPD 急性加重中的应用。
通过 PubMed Medline(1950 年-2014 年 2 月)和 Embase(1950 年-2014 年 2 月)检索文献,使用皮质类固醇、COPD、慢性支气管炎、肺气肿和加重等检索词。从已确定的出版物中审查所有参考文献,以确定是否可能包含。综述并总结了所有评估全身皮质类固醇治疗 AECOPD 疗效的随机、安慰剂对照试验、荟萃分析和系统评价。
评估了 AECOPD 治疗中皮质类固醇的给药。与安慰剂相比,全身皮质类固醇可改善气流,降低治疗失败率和复发风险,可能改善症状并缩短住院时间。因此,所有主要指南都建议在治疗 AECOPD 中使用皮质类固醇。现有文献表明,低剂量口服皮质类固醇与高剂量静脉皮质类固醇方案一样有效,同时最大限度地减少不良反应。最近的数据表明,较短时间的皮质类固醇治疗与目前指南推荐的传统治疗时间一样有效。
全身皮质类固醇在治疗 AECOPD 中有效,被认为是治疗 AECOPD 患者的标准治疗方法。因此,全身皮质类固醇应给予所有因 AECOPD 而寻求紧急医疗护理的患者。应考虑使用最低有效剂量和最短疗程。